Can-Fite BioPharma (NYSE:CANF) Receives New Coverage from Analysts at StockNews.com

StockNews.com initiated coverage on shares of Can-Fite BioPharma (NYSE:CANF) in a research note published on Thursday morning. The brokerage issued a hold rating on the stock.

Separately, HC Wainwright restated a buy rating and issued a $18.00 target price on shares of Can-Fite BioPharma in a research note on Thursday, May 9th.

Can-Fite BioPharma Stock Up 6.4 %

Can-Fite BioPharma stock opened at $3.47 on Thursday. The company has a market capitalization of $12.28 million, a PE ratio of -1.94 and a beta of 1.45. Can-Fite BioPharma has a 12-month low of $1.81 and a 12-month high of $4.48. The firm’s fifty day moving average is $2.57 and its 200 day moving average is $2.27.

Institutional Inflows and Outflows

An institutional investor recently bought a new position in Can-Fite BioPharma stock. Schechter Investment Advisors LLC purchased a new stake in Can-Fite BioPharma Ltd. (NYSE:CANF) during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The firm purchased 20,077 shares of the company’s stock, valued at approximately $44,000. Schechter Investment Advisors LLC owned approximately 0.57% of Can-Fite BioPharma as of its most recent filing with the Securities and Exchange Commission. 21.00% of the stock is currently owned by institutional investors.

Can-Fite BioPharma Company Profile

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19.